The National Institute for Health and Care Excellence

'I could go to work again': prescriptions for NICE-recommended endometriosis and fibroid tablets soar

NICE recommends the tablets for adults with moderate to severe fibroid symptoms. Linzagolix is recommended for longer-term treatment, with the dose depending on the patient. For endometriosis, they ...
National Institute for Health and Care Excellence

Quality statement 2: Venous thromboembolism risk assessment for people with lower limb immobilisation

A significant number of people are discharged after hospital treatment for trauma or orthopaedic surgery with temporary lower limb immobilisation. These people may have an increased risk of VTE, but ...
National Institute for Health and Care Excellence

Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]

Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043] ...
National Institute for Health and Care Excellence

Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal)

Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) Technology appraisal guidance TA987 Published: 10 July 2024 Register as a ...
National Institute for Health and Care Excellence

Baricitinib for treating severe alopecia areata

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...
National Institute for Health and Care Excellence

Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer

This guidance has been updated and replaced by NICE technology appraisal guidance 946 ...
National Institute for Health and Care Excellence

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges

This guideline covers interventions and support for children, young people and adults with a learning disability and behaviour that challenges. It highlights the importance of understanding the cause ...
National Institute for Health and Care Excellence

Artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment

We have moved health technology evaluation 12 to become HealthTech guidance 696. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme ...
National Institute for Health and Care Excellence

Intrapartum care

This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give ...
National Institute for Health and Care Excellence

Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over

Evidence-based recommendations on dabrafenib (Finlee) with trametinib (Spexotras) for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over. There are simple ...
National Institute for Health and Care Excellence

Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment

There is a simple discount patient access scheme for zanidatamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...